Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zivo BioscienceZIVO 8 PS Ratio is 71.79 as of Aug. 08, 2026, which is 90% below its 10-year median of 721.89. GuruFocus rates ZIVO with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 929 Biotechnology companies, Zivo Bioscience ranks worse than 82.35% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Zivo Bioscience's share price is $4.02.
Zivo Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 was $0.06. Hence, Zivo Bioscience's PS Ratio for today is 71.79.
The historical rank and industry rank for Zivo Bioscience's PS Ratio or its related term are showing as below:
ZIVO'
s PS Ratio Range Over the Past 10 Years
Min: 21.43 Med: 721.89 Max: 4840
Current: 71.79
During the past 13 years, Zivo Bioscience's highest PS Ratio was 4840.00. The lowest was 21.43. And the median was 721.89.
ZIVO's PS Ratio is ranked worse than 82.35% of 929
companies
in the Biotechnology industry
Industry Median: 9.49
vs ZIVO: 71.79
During the past 13 years, Zivo Bioscience's highest 3-Year average Revenue per Share Growth Rate was 247.10% per year. The lowest was -50.20% per year. And the median was -13.70% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Zivo Bioscience PS Ratio Related Terms
Zivo Bioscience PS Ratio Historical Data
* Premium members only.
The historical data trend for Zivo Bioscience's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zivo Bioscience's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zivo Bioscience PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zivo Bioscience's PS Ratio distribution charts can be found below:
* The bar in red indicates where Zivo Bioscience's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Zivo Bioscience's Share Price of today is $4.02. Zivo Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Zivo Bioscience (ZIVO) has a PS Ratio of 71.79 as of Aug. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zivo Bioscience and its competitors. This is 90% below median its historical median of 721.89. Over the past decade, Zivo Bioscience's PS Ratio has ranged from 21.43 to 4,840.00. According to the industry distribution chart, Zivo Bioscience ranks #765 out of 929 companies in the Biotechnology industry, placing it in the top 82.3%.
Is Zivo Bioscience's PS Ratio too high?
Zivo Bioscience's current PS Ratio of 71.79 is 90% below median its 10-year median of 721.89. Over the past 10 years, this metric has ranged from a low of 21.43 to a high of 4,840.00. The Biotechnology industry median PS Ratio is 9.49. Zivo Bioscience's value of 71.79 is 656.5% above this industry median. Based on the distribution chart, Zivo Bioscience ranks #765 out of 929 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zivo Bioscience has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Zivo Bioscience's PS Ratio compare to CVM and HOWL?
According to the Biotechnology industry distribution chart, Zivo Bioscience ranks #765 out of 929 companies for PS Ratio. This places Zivo Bioscience in the lower half of its industry. The industry median PS Ratio is 9.49. Zivo Bioscience's value of 71.79 is 656.5% above this benchmark. Historically, Zivo Bioscience's own PS Ratio has ranged from 21.43 to 4,840.00 over the past decade. While the company's 10-year median is 721.89 vs. the industry median of 9.49, Zivo Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.49, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zivo Bioscience's current PS Ratio of 71.79 is 656.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zivo Bioscience and its competitors. For the Biotechnology industry, the median PS Ratio is 9.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zivo Bioscience's current PS Ratio is 71.79, which is 90% below median its own 10-year median of 721.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zivo Bioscience stock overvalued right now?
Zivo Bioscience (ZIVO) has a current PS Ratio of 71.79. The current PS Ratio is 71.79, which is 90% below median its 10-year median of 721.89 and 656.5% above the Biotechnology industry median of 9.49. Zivo Bioscience's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Zivo Bioscience (ZIVO), the current PS Ratio is 71.79 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zivo Bioscience Inc operates in one reportable segment microalgae technology. The segment is research and development operating in both the therapeutic and nutritional sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's applications are ANIMAL APPLICATIONS, HUMAN APPLICATIONS.
8GF Score
Get the complete analysis for ZIVO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZIVO has been successfully added to your 
